A corneal transplant lawsuit typically arises when a patient suffers significant vision loss or eye damage requiring corneal transplant surgery due to medical negligence, defective medications, or preventable injuries. These cases have emerged most prominently from complications linked to Oxervate, a prescription eye drop approved by the FDA in 2018 for treating neurotrophic keratitis. Between 2019 and early 2024, the FDA documented over 6,497 adverse events related to Oxervate, with more than 4,461 categorized as eye disorders—including 45 cases where patients required corneal transplant surgery to restore or salvage their vision.
One documented case involved a patient who suffered severe corneal damage from Oxervate treatment, necessitating a full corneal transplant after the medication caused irreversible corneal deposits and painful epithelial plaques not previously disclosed on the drug’s safety label. Corneal transplant lawsuits seek compensation for the substantial medical costs, vision loss, and ongoing complications that patients face following surgery. The procedure itself—which ranges from $24,000 to $55,000 depending on the type of transplant and geographic location—is typically covered by insurance when medically necessary. However, when the need for transplant surgery results from a defective product, inadequate medical care, or pharmaceutical negligence, victims may pursue legal action to recover damages for surgery costs, lost vision, pain and suffering, and permanent disability.
Table of Contents
- What Triggers a Corneal Transplant Lawsuit?
- Understanding Corneal Transplant Costs and Medical Damages
- Documented Settlement Examples and Verdict Patterns
- The Oxervate Medication Litigation Landscape
- Common Complications After Corneal Transplant Surgery and Legal Implications
- Establishing Causation in Corneal Transplant Lawsuits
- The Future of Corneal Transplant Litigation and Emerging Issues
- Conclusion
What Triggers a Corneal Transplant Lawsuit?
Corneal transplant lawsuits can originate from several distinct sources: medication-related corneal damage, chemical or traumatic eye injuries where medical providers failed to provide adequate treatment, and surgical complications arising from negligent eye care. The most significant wave of cases has centered on Oxervate, which a peer-reviewed analysis published in Expert Opinion on Drug Safety identified 3,288 adverse event cases between 2018 and 2022, uncovering 50 ocular-related complications that were not disclosed on the medication’s original safety label. These findings suggest that patients who suffered corneal damage from Oxervate may have lacked informed consent about the true risks they faced. Beyond pharmaceutical cases, lawsuits also emerge from workplace or environmental injuries where inadequate emergency treatment led to permanent corneal scarring.
For example, a documented settlement of $500,000 involved a patient who suffered a chemical splash injury to the eye but received inadequate irrigation in the immediate aftermath, resulting in corneal damage severe enough to require transplant surgery. The defendant’s failure to properly manage the acute injury directly caused the need for surgical intervention. A third category involves surgical malpractice, where complications arising from one eye surgery necessitate a corneal transplant. These cases hinge on proving that the original surgeon’s negligence—whether through improper technique, failure to monitor complications, or inadequate post-operative care—directly led to the corneal damage requiring transplant.
Understanding Corneal Transplant Costs and Medical Damages
A corneal transplant is a significant surgical intervention with substantial financial consequences. The procedure itself ranges from $24,000 to $55,000, with costs varying based on whether the patient undergoes a full-thickness keratoplasty (traditional corneal transplant), a partial-thickness procedure, or an endothelial keratoplasty—a more specialized technique. Additional expenses include pre-operative testing, post-operative medications (typically required for months or years), follow-up surgeon visits, and potential re-transplantation if the graft fails. Most insurance plans cover corneal transplants when deemed medically necessary, but the patient’s out-of-pocket costs—deductibles, co-payments, and potentially non-covered services—can still reach thousands of dollars. One critical limitation of corneal transplant lawsuits involves the fact that corneal transplants generally have high success rates.
Studies show that 80-90% of corneal transplants achieve functional improvement, with graft survival rates remaining strong even years after surgery. This success rate complicates damages calculations in some cases, because a defendant’s counsel may argue that the transplant effectively “fixed” the problem and that ongoing damages are limited. However, this argument ignores the fact that patients endure surgery recovery, take immunosuppressant eye drops indefinitely to prevent graft rejection, face the risk of graft failure, and may experience reduced vision compared to their pre-injury baseline. Another limitation worth noting: if a patient had pre-existing corneal disease or refractive error before the incident leading to the lawsuit, establishing that the defendant’s actions directly necessitated the transplant becomes more complex. Courts typically require clear evidence that the injury or medication was the primary cause of the corneal damage requiring surgery, not merely a contributing factor to an already-compromised eye.
Documented Settlement Examples and Verdict Patterns
Settlement amounts in corneal transplant cases vary widely depending on the severity of vision loss, the plaintiff’s age and occupation, and the defendant’s culpability. A settlement of $500,000 was reached in a medical malpractice case where inadequate emergency eye care following a chemical splash resulted in corneal damage necessitating transplant surgery. In that case, the plaintiff experienced progressive vision loss and ultimately suffered bleeding behind the eye following the transplant, leading to total vision loss in that eye—a devastating outcome that reflects the upper range of damages. Another prominent settlement involved a construction worker who suffered an acute eye injury at the workplace.
Despite undergoing emergency care and three separate eye procedures—including a corneal transplant—the plaintiff lost nearly all vision in the injured eye. This case ultimately settled for $1,300,000 at private mediation, even though the plaintiff had no significant lost-wage claim due to the nature of the injury and recovery. The settlement amount reflected the permanent nature of the vision loss, the psychological impact of near-blindness, and the ongoing medical expenses for graft maintenance and potential future surgeries. These settlements demonstrate that corneal transplant cases often involve permanent, catastrophic vision loss rather than temporary injury. Unlike some litigation outcomes where a plaintiff fully recovers, corneal transplant cases typically involve lifelong complications, continued medical dependence, and permanent functional impairment.
The Oxervate Medication Litigation Landscape
Oxervate has become the focal point of corneal transplant litigation in recent years. Approved by the FDA in 2018 for the treatment of neurotrophic keratitis—a rare corneal disorder characterized by reduced corneal sensation—Oxervate was marketed as a breakthrough treatment. However, post-market surveillance revealed a concerning safety profile not fully captured in the original clinical trials. Between 2019 and early 2024, the FDA received 6,497 adverse event reports associated with Oxervate, with 4,461 of these categorized as eye disorders ranging from minor irritation to severe complications.
The most alarming finding came from a comprehensive peer-reviewed analysis that reviewed 3,288 cases of Oxervate-related adverse events between 2018 and 2022. This study, published in Expert Opinion on Drug Safety, identified 50 ocular-related side effects that were not disclosed on the medication’s approved safety label. These undisclosed complications included painful epithelial plaques, irreversible corneal deposits, and other forms of corneal damage that in 45 documented cases progressed to the point where patients required corneal transplant surgery. The failure to disclose these risks raises significant product liability questions: did patients and physicians have adequate information to make informed treatment decisions? This tradeoff between aggressive treatment of rare conditions and full transparency about risks remains a central tension in pharmaceutical litigation. Oxervate addressed an unmet medical need for patients with neurotrophic keratitis, but the gap between disclosed and actual adverse effects—particularly the 45 cases requiring transplantation—suggests that patients may have chosen alternative treatments had they known the true risk profile.
Common Complications After Corneal Transplant Surgery and Legal Implications
While corneal transplants have high overall success rates, post-operative complications can still occur and may form the basis for additional legal claims. The most common complication is graft rejection, where the patient’s immune system attacks and destroys the donor cornea. This occurs in approximately 10-20% of transplants within the first year, though immunosuppressant eye drops significantly reduce this risk. A warning for litigation purposes: graft rejection itself is a recognized risk of the procedure, so a patient cannot typically sue solely because rejection occurred. However, if the surgeon failed to monitor the patient adequately or delayed treatment of early rejection signs, leading to irreversible graft failure, a malpractice claim may be viable. Another significant complication is corneal ectasia or weakening of the corneal structure, which can develop months or years after transplant.
In rare cases, this leads to a need for re-transplantation. Infection remains a persistent risk, particularly in the immediate post-operative period or if the patient fails to adhere to prescribed eye drop regimens. Astigmatism—irregular curvature that causes blurred vision—commonly develops after transplant and may require glasses, contact lenses, or additional surgical correction. A critical limitation in these secondary complication cases: the law typically distinguishes between known risks disclosed to the patient and negligent surgical outcomes. If a complication is a recognized, unavoidable risk of the procedure that was disclosed in the informed consent process, the patient generally cannot recover damages simply because the complication occurred. Legal recovery requires proving either negligence in surgical technique, failure to properly monitor for complications, or inadequate disclosure of material risks.
Establishing Causation in Corneal Transplant Lawsuits
Causation—proving that the defendant’s actions directly led to the need for corneal transplant surgery—is often the most challenging element of these cases. In Oxervate litigation, causation becomes easier when a patient can document that they were prescribed the medication, used it as directed, developed progressive corneal damage, and ultimately required transplant surgery. Medical records showing the temporal relationship between Oxervate use and corneal complications are essential evidence.
In surgical malpractice cases, causation requires expert testimony establishing that the surgeon’s negligence directly caused the corneal damage. For example, if a surgeon performed refractive surgery (LASIK or similar) and created a complication through inadequate surgical technique or inadequate laser calibration, an expert ophthalmologist can testify that the negligence directly led to corneal scarring requiring transplant. The burden is on the plaintiff to establish this causal chain with medical certainty or, at minimum, medical probability.
The Future of Corneal Transplant Litigation and Emerging Issues
The landscape of corneal transplant litigation continues to evolve as additional medications and medical devices come under scrutiny. Beyond Oxervate, attention has focused on other eye medications and topical treatments that may increase corneal complication risks. Additionally, as corneal cross-linking—a newer treatment to strengthen the cornea—becomes more widely adopted, litigation may emerge from complications of this procedure.
Looking forward, the resolution of Oxervate litigation through settlements or verdict may set precedent for other pharmaceutical cases involving inadequate adverse event disclosure. If courts determine that manufacturers bear responsibility for the gap between disclosed risks and actual adverse effects documented in post-market surveillance, this may influence how other pharmaceutical companies monitor and disclose safety data. For patients who have suffered corneal damage, the evolving legal landscape provides both opportunities for recovery and the necessity to act within applicable statutes of limitations before claims expire.
Conclusion
A corneal transplant lawsuit addresses one of the most serious forms of medical injury—permanent vision loss requiring major surgical intervention. Whether arising from medication complications like those associated with Oxervate, traumatic or chemical injuries with inadequate emergency treatment, or surgical negligence, these cases seek to compensate patients for the substantial costs, permanent disability, and diminished quality of life that result from corneal transplantation.
The documented settlements in these cases, ranging from $500,000 to $1.3 million, reflect the catastrophic nature of corneal injuries and the lasting consequences patients endure. If you or a family member has suffered corneal damage requiring transplant surgery following use of a medication, a workplace injury, or medical malpractice, consulting with an attorney experienced in ophthalmology litigation can help determine whether you have a viable claim and what damages you may be entitled to recover. Time is critical, as statutes of limitations vary by state and circumstance.